文献速递神经肿瘤神经重症

脑微透析评估脑肿瘤化疗药物递送的技术综述

Cerebral Microdialysis as a Tool for Assessing the Delivery of Chemotherapy in Brain Tumor Patients.
PubMed 文献 · World Neurosurg · 2020-09-02

该综述基于PubMed文献检索,总结了脑微透析(CMD)在脑肿瘤药物递送评估中的技术、原理和新数据。CMD可采集间质液,获取药物跨血脑屏障的药代动力学数据和化疗反应的代谢数据,虽无并发症报告但存在风险和局限性。CMD是有价值但未充分利用的技术,未来在体内评估药物递送至肿瘤细胞方面将起核心作用。

要点

  • CMD可采集脑间质液,直接评估药物跨血脑屏障的渗透情况
  • CMD可获取药代动力学和代谢数据,表征化疗反应
  • CMD技术存在风险和局限性,患者需在ICU监测

核心结论

  • CMD是评估脑肿瘤药物递送的有价值但未充分利用的技术,未来在体内评估药物递送至肿瘤细胞方面将起核心作用。

研究设计与样本

  • 综述,通过PubMed数据库检索文献,选择在动物脑肿瘤模型或临床试验中使用CMD的研究,并审查参考文献获取额外信息。

主要发现

  • CMD允许收集药物跨血脑屏障渗透的药代动力学数据和表征化疗反应的代谢数据。
  • 动物CMD实验已用于排除中枢神经系统药物候选物进入临床试验。
  • 目前接受CMD的患者因需连接设备而在重症监护室监测,但微小型化进展有望改变这一情况。
  • 未报告CMD相关并发症,但当前技术存在风险和局限性。

临床怎么用

  • CMD可用于评估化疗药物在脑肿瘤患者中的递送和药效,指导临床试验决策。
  • 动物CMD实验可筛选中枢神经系统药物候选物,避免无效药物进入临床试验。

局限性

  • 当前CMD技术存在风险和局限性,患者需在ICU监测且连接设备限制活动。
  • 综述未报告CMD相关并发症,但技术本身并非无风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of curative treatment for glioblastoma has been extremely challenging. Chemotherapeutic agents that have seemed promising have failed in clinical trials. Drugs that can successfully target cancer cells within the brain must first traverse the brain interstitial fluid. Cerebral microdialysis (CMD) is an invasive technique in which interstitial fluid can be directly sampled. CMD has primarily been used clinically in the setting of head trauma and subarachnoid hemorrhage. Our goal was to review the techniques, principles, and new data pertaining to CMD to highlight its use in neuro-oncology. We conducted a literature search using the PubMed database and selected studies in which the investigators had used CMD in either animal brain tumor models or clinical trials. The references were reviewed for additional information. Studies of CMD have shown its importance as a neurosurgical technique. CMD allows for the collection of pharmacokinetic data on drug penetrance across the blood-brain barrier and metabolic data to characterize the response to chemotherapy. Although no complications have been reported, the current CMD technique (as with any procedure) has risks and limitations, which we have described in the present report. Animal CMD experiments have been used to exclude central nervous system drug candidates from progressing to clinical trials. At present, patients undergoing CMD have been monitored in the intensive care unit, owing to the requisite tethering to the apparatus. This can be expected to change soon because of advances in microminiaturization. CMD is an extremely valuable, yet underused, technique. Future CMD applications will have central importance in assessing drug delivery to tumor cells in vivo, allowing a pathway to successful therapy for malignant brain tumors.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Pierce CF, Kwasnicki A, Lakka SS, et al. Cerebral Microdialysis as a Tool for Assessing the Delivery of Chemotherapy in Brain Tumor Patients. World Neurosurg. 2020. PMID: 32890850. doi:10.1016/j.wneu.2020.08.161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。